Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
121-140 of 1,694 trials

Neuroendocrine Tumors: 177Lu-edotreotide vs. Everolimus

We are studying whether a new treatment, 177Lu-edotreotide, can help patients with neuroendocrine tumors of the lung and thymus live longer without disease progression compared to everolimus.

Neuroendocrine Tumor>2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesOncology

Hydroxychloroquine for Extra-pulmonary Sarcoidosis

We are studying whether hydroxychloroquine can reduce the need for steroids in patients with extra-pulmonary sarcoidosis. This trial will also look at its effects on quality of life and potential side effects.

Sarcoidosis>2 yearsConfirmation phase (III)Standard MedicinesInternal MedicineRheumatology

Chronic Spontaneous Urticaria: Remibrutinib for Teens

We are studying a new medication, remibrutinib, for adolescents with chronic spontaneous urticaria that isn't well controlled by antihistamines. The goal is to see if it can reduce symptoms like hives and itching more effectively than a placebo.

Chronic Spontaneous Urticaria3-6 monthsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesAllergologyDermatology

Kidney Disease: Iptacopan (LNP023) Study

We are testing a new medication for people with idiopathic immune complex mediated membranoproliferative glomerulonephritis to see if it reduces protein in urine and improves kidney function. The study also evaluates how well patients feel while using this treatment.

Idiopathic Immune Complex Mediated Membranoproliferative GlomerulonephritisConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Chronic Graft-Versus-Host Disease: Axatilimab and Ruxolitinib Study

We are studying a new treatment combining axatilimab and ruxolitinib for people newly diagnosed with chronic graft-versus-host disease. The goal is to see if this combination is safe and effective in improving their condition.

Chronic Graft-Versus-Host Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementAllergologyHematologyInternal Medicine

Atorvastatin for Preventing Episodic Migraines

We are studying whether atorvastatin can help reduce the frequency of episodic migraines in participants. This trial will also look at how well different doses work and any side effects that may occur.

Migraine3-6 monthsEfficacy phase (II)≤5 visitsStandard MedicinesNeurology

Chronic Migraine: Atorvastatin Study

We are investigating whether atorvastatin can help prevent chronic migraines in adults. The study will also assess how many people respond to the treatment and any potential side effects.

Chronic MigraineEfficacy phase (II)Standard MedicinesInternal MedicineNeurology

Kidney Disease: ALE.F02 Treatment Study

We are testing a new intravenous treatment, ALE.F02, for patients with rapidly progressive glomerulonephritis linked to AAV. The study aims to see if it can help protect kidney function and assess its safety.

Rapidly Progressive Glomerulonephritis6-12 monthsEfficacy phase (II)Investigational MedicinesInternal MedicineNephrology

Atopic Dermatitis: Amlitelimab Injection Study

We are evaluating the long-term safety and effectiveness of amlitelimab injections for individuals aged 12 and older with moderate to severe atopic dermatitis. This study aims to understand how the treatment impacts their symptoms and overall quality of life.

Atopic Dermatitis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyDermatology

Guselkumab for Children with Ulcerative Colitis

We are studying whether guselkumab can effectively treat moderately to severely active ulcerative colitis in children. This trial will help us understand its safety and how well it works over time.

Ulcerative Colitis1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics

Heart Failure: Comparing Spironolactone and Eplerenone

We are studying whether spironolactone or eplerenone is more effective in reducing the risk of death for patients with heart failure. This trial is for those receiving treatment in a heart failure clinic.

Heart Failure>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

Prostate Cancer: Metastasis-Directed Therapy Study

We are investigating if a new treatment can improve survival for men with castration-refractory prostate cancer and a few progressive lesions. This study compares the new approach to standard care to see which is more effective.

Oligoprogressive Metastatic Castration-Refractory Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesOncologyUrology

Infliximab for Non-Crohn Anal Fistulas

We are studying whether Infliximab can improve healing in patients with complex anal fistulas after surgery. This trial aims to find out if this treatment helps reduce complications and improve recovery.

Anal Fistula>2 yearsEfficacy phase (II)Standard MedicinesGastroenterologyInternal Medicine

High-Grade Glioma: Abemaciclib with Temozolomide

We are studying whether adding abemaciclib to temozolomide helps children and young adults with newly diagnosed high-grade glioma after radiotherapy. This trial compares the combination treatment to temozolomide alone.

GliomaEfficacy phase (II)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncologyPediatrics

Pramipexole for Anhedonic Depression

We are studying the long-term effects of adding pramipexole to treatment for people with anhedonic depression. The goal is to see how well it works and how well patients tolerate it.

Depression>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePsychiatry

AR Positive Triple-Negative Breast Cancer: Bicalutamide and Abemaciclib Study

We are studying a combination of bicalutamide and abemaciclib for patients with AR positive triple-negative breast cancer. The goal is to see if this treatment helps control the disease and to evaluate its safety.

Locally Advanced Unresectable or Metastatic Androgen Receptor Positive Triple Negative Breast Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementOncology

Polycythemia Vera: Givinostat vs. Hydroxyurea

We are studying a new treatment called Givinostat for patients with high-risk Polycythemia Vera to see if it works better and is safer than the standard medication, hydroxyurea.

Polycythemia Vera1-2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal Medicine

Focal-Onset Seizures: Study of XEN1101

We are testing a new medication, XEN1101, to see if it can help reduce the frequency of focal-onset seizures. This study compares its effects to a placebo in participants with this condition.

Focal Epilepsy6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Epilepsy: Long-term Study of XEN1101

We are examining the safety and effectiveness of XEN1101 for adults with epilepsy. This study looks at how well it reduces seizures and improves quality of life over time.

Generalized Tonic-Clonic SeizuresFocal Epilepsy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Recurrent Prostate Cancer: SpectraCure P18 System Study

We are evaluating a new treatment system using lasers and a drug for men with recurrent prostate cancer. The study aims to ensure safety and effectiveness in targeting and eliminating cancer cells.

Recurrent Prostate CancerSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesOncology